Preventing HIV with Gilead Science's Truvada

Tenofovir

Gilead Science, makers of Tamiflu currently are in Phase III trials for the anti-HIV medicine Truvada. Gilead, the global leader in treatments for human immunodeficiency virus that causes AIDS, derives 80 percent of its $5 billion in annual sales from AIDS treatments. The company markets Atripla, a three-in-one daily pill containing its dual drug pill Truvada plus Bristol-Myers Squibb Co.’s Sustiva.

President and COO of Gilead Sciences Inc. (GILD) John F Milligan.
 
“The fixed dose Quad pill is the most exciting thing we’re working on,” Milligan said.